Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72722 record(s)

Req # A-2023-000779

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-102700- 258.

Organization: Health Canada

29 page(s)
January 2024

Req # A-2023-000784

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-106488-990.

Organization: Health Canada

23 page(s)
January 2024

Req # A-2023-000836

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-101473-308.

Organization: Health Canada

21 page(s)
January 2024

Req # A-2023-000837

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103099-693.

Organization: Health Canada

25 page(s)
January 2024

Req # A-2023-000847

Adverse Drug Reactions (ADRs) for Tavneos. Report numbers: E2B_06476280, E2B_06503137. ADR for Rexulti: E2B_06469898. ADR for Rexulti. Report number: E2B_06469898. ADR for Rexulti and Aripiprazole. Report number: E2B_06501539. ADRs for Ablify…

Organization: Health Canada

121 page(s)
January 2024

Req # A-2023-000848

Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_00539952, E2B_00897836, E2B 00941720, E2B_01562153, E2B_01565942, E2B_02147049, E2B_01141776, E2B_00622627, E2B_01124955, 000649045.

Organization: Health Canada

329 page(s)
January 2024

Req # A-2023-000885

Adverse Drug Reactions (ADRs). Report numbers: E2B_05723103, 001047899, 001049502, 001051502, E2B_06524635, E2B_06515895, E2B_06523800.

Organization: Health Canada

614 page(s)
January 2024

Req # A-2023-000887

Adverse Drug Reactions (ADRs). Report numbers: E2B_03502706, 001035382, 001027439, 001033519, 001023452, E2B_02076775, E2B_06026557, E2B_05463299, E2B_06044179, E2B_06257918.

Organization: Health Canada

158 page(s)
January 2024

Req # A-2023-000905

Adverse Drug Reaction (ADR) for Dexilant. Report numbers: E2B_06478163. ADRs for Entyvio. Report numbers: E2B_06491377, E2B_06483795, E2B_06474147, E2B_06504786, E2B_06505517. ADR for Ixazomib. Report number: E2B_06519150. ADR for Ondansetron.…

Organization: Health Canada

777 page(s)
January 2024

Req # A-2023-000907

Adverse Drug Reactions (ADRs) for Pantoprazole sodium. Report numbers: E2B_06469121, E2B_06470221, E2B_06486220, E2B_06511160, E2B_06503947, E2B_06486943. ADRs for Mesalamine. Report numbers: E2B_06504252, 001048385, E2B_06525848, E2B_06523386.

Organization: Health Canada

298 page(s)
January 2024
Date modified: